The following article is a part of Ophthalmology Advisor’s conference coverage of the Southeastern Educational Congress of Optometry (SECO) 2021, held in Atlanta and virtually from April 28 to May 2, 2021. The team at Ophthalmology Advisor will be reporting on the presentations offered by these leading experts in optometry and ophthalmology. Check back for more from the SECO 2021 Meeting.
The “future” of anterior segment advances — from intraocular lens (IOL) updates to advances in postoperative care — will be covered in a special session at the 2021 Southeastern Educational Congress of Optometry (SECO), held April 28 to May 2 in Atlanta, Georgia.1
John Berdahl, MD, of Vance Thompson Vision in Sioux Falls, South Dakota, and Lawrence Woodard, MD, of Omni Eye Services in Atlanta, GA, rely on their own case studies to offer attendees a peek into their expertise on various anterior segment findings.
Previously, Drs Berdhal and Woodard presented on the topic of emerging technologies in the next 5 years. These technologies included insertable, punctal, and intraocular drug delivery systems.
This year, Drs Berdhal and Woodard will cover numerous topics, beginning with glaucoma. Specifically, they will discuss treatment options that range from drops to new noninvasive approaches, contextualizing the fact only 20% and 15% of patients report persistently good adherence to topical glaucoma medication adherence in the 1- and 4-year periods following an open-angle glaucoma diagnosis.2
Next, the presenters will discuss ocular surface disease, sharing data from a 2010 study published in Cornea.3 These data show that ocular surface disease is common among people with glaucoma, and those using 3 topical medications had significantly higher Ocular Surface Disease Index Scores compared with those using only 1 type of topical drop. Unfortunately, the many protective barriers of the eye restrict bioavailability of many applied topical agents; as a solution. Drs Berdhal and Woodard posit that solutions such as injectable, intraocular, or ocular surface drug delivery devices may be of value to this patient population.
The options available include Durysta™(bimatoprost implant, Allergan), an intracameral, biodegradable, sustained-release implant to lower intraocular pressure (IOP), and iDose™ (travoprost intraocular implant, Glaukos), a currently in phase 2 clinical trials (ClinicalTrials.gov identifier NCT04615403).
Minimally invasive glaucoma surgery (MIGS) options include the iStent inject® (Glaukos) and the Hydrus® Microstent (Ivantis). MIGS comanagement topics will also be covered, including postoperative procedures for day 1, week 1, and month 1.
Drs Berdhal and Woodard will also review the newest US Food and Drug Administration (FDA)-approved premium IOL technologies, including light adjustable lenses, the PanOptix® Trifocal (Alcon), the Acrysof® IQ Vivity™ (Alcon), and the Tecnis Symfony® Plus.
Disclosure: Presenters declared affiliations with biotech, pharmaceutical, or medical device companies. Please see the original reference for a full list of authors’ disclosures.
Visit Ophthalmology Advisor’s conference section for complete coverage of the SECO 2021 Meeting and more.
- Berdahl J, Woodard L. Anterior segment advances: The future is now! Presented at: Southeastern Educational Congress of Optometry (SECO) 2021 Annual Meeting; April 28-May 2, 2021; Atlanta, GA. Course 62
- Newman-Casey PA, Blachley T, Lee PP, Heisler M, Farris KB, Stein JD. Patterns of glaucoma medication adherence over four years of follow-up. Ophthalmolo. 2015;122(10):2010-2021. doi:10.1097/ICO.0b013e3181c325b2
- Fechtner RD, Godfrey DG, Budenz D, Stewart JA, Stewart WC, Jasek MC. Prevalence of ocular surface complaints in patients with glaucoma using topical intraocular pressure-lowering medications. Cornea. 2010(29)6:618-621. doi:10.1016/j.ophtha.2015.06.039